TNSN97084A1 - BIARYL ACETYLENES AS INHIBITORS OF METALLOPROTEINASE MATRICES - Google Patents
BIARYL ACETYLENES AS INHIBITORS OF METALLOPROTEINASE MATRICESInfo
- Publication number
- TNSN97084A1 TNSN97084A1 TNTNSN97084A TNSN97084A TNSN97084A1 TN SN97084 A1 TNSN97084 A1 TN SN97084A1 TN TNSN97084 A TNTNSN97084 A TN TNSN97084A TN SN97084 A TNSN97084 A TN SN97084A TN SN97084 A1 TNSN97084 A1 TN SN97084A1
- Authority
- TN
- Tunisia
- Prior art keywords
- disease
- compounds
- conditions
- matrices
- treating
- Prior art date
Links
- 102000005741 Metalloproteases Human genes 0.000 title abstract 3
- 108010006035 Metalloproteases Proteins 0.000 title abstract 3
- -1 BIARYL ACETYLENES Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010053555 Arthritis bacterial Diseases 0.000 abstract 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010060820 Joint injury Diseases 0.000 abstract 1
- 208000015775 Mandibular disease Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 208000002528 coronary thrombosis Diseases 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
LA MATRICE METALLOPROTEASE INHIBITANT LES COMPOSES, LES COMPOSITIONS PHARMACEUTIQUES ET LA METHODE DE TRAITEMENT DE LA MALADIE EN UTILISANT CES COMPOSES SONT PRESENTES. LES COMPOSES DE CETTE INVENTION ONT LES FORMULES GENERALISEES : R45 EST SELECTIONNE DU GROUPE COMPRENANT : HOCH2, M2OCH2, (n-Pr)2NCH2, CH3,CH2CG2, ETOCO2 CH2, HO (CH2), CH3 (CH2) 2, HO2C(CH2)2, OHC(CH2)3, HO(CH2)4, Ph, 3-HO-Ph and PhCH2OCH2 ; and R 16 is. CES COMPOSES SONT UTILES POUR INHIBITANT LES MATRICES METALLOPROTEASES ET COMBATTANT LES CONDITIONS OU MMP’s : ALLEGER LES EFFETS D’OSTEOARTHRITIS. RHEUMATOID ARTHRISTIS, ARTHRITIS SEPTIQUE, MALADIE PERIODONTALE, ULCERATION DE LA CORNEE, PROTEINURIA. MALADIE ANEURYSMAL AORTIQUE. EPIDERMLYSIS DISTROPHOBIQUE, BULLOSA, DES CONDITIONS MENANT A DES REACTIONS INFLAMMATOIRES, OSTEOPENIAS EN MEDIATION PAR L’ACTIVITE MMP. MALADIE TEMPERO MANDIBULAIRE DES JOINTS, DES MALADIES DEMYELANTE DU SYSTEME NERVEUX : RETARDER LA TUMEUR METASTASIS ET LA PERTE DEGENERATIVE DU CARTILAGE SUIVANT UNE BLESSURE TRAUMATIQUE DES JOINTS : REDUIT LA THROMBOSIS CORONAIRE DE LA RUPTURE DE LA PLAQUE ATHROSCLEROTIQUE : OU CETTE PRESENTE INVENTION DONNE AUSSI DES COMPOSITIONS ET METHODES PHARMACEUTIQUES POUR TRAITER CES CONDITIONS.THE METALLOPROTEASE MATRIX INHIBITING COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THE METHOD OF TREATING DISEASE USING THESE COMPOUNDS ARE PRESENT. THE COMPOUNDS OF THIS INVENTION HAVE THE GENERALIZED FORMULAS: R45 IS SELECTED FROM THE GROUP INCLUDING: HOCH2, M2OCH2, (n-Pr) 2NCH2, CH3, CH2CG2, ETOCO2 CH2, HO (CH2), CH3 (CH2) 2, HO2C (CH2) 2, OHC (CH2) 3, HO (CH2) 4, Ph, 3-HO-Ph and PhCH2OCH2; and R 16 is. THESE COMPOUNDS ARE USEFUL FOR INHIBITING METALLOPROTEASE MATRICES AND COMBATTING CONDITIONS OR MMP’s: ALLEVIATING THE EFFECTS OF OSTEOARTHRITIS. RHEUMATOID ARTHRISTIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, ULCERATION OF THE CORNEA, PROTEINURIA. AORTIC ANEURYSMAL DISEASE. DISTROPHOBIC EPIDERMLYSIS, BULLOSA, CONDITIONS LEADING TO INFLAMMATORY REACTIONS, OSTEOPENIAS MEDIATED BY MMP ACTIVITY. TEMPERO-MANDIBULAR DISEASE OF JOINTS, DEMYELANT DISEASE OF THE NERVOUS SYSTEM: DELAYING METASTASIS TUMOR AND DEGENERATIVE LOSS OF CARTILAGE FOLLOWING TRAUMATIC JOINT INJURY: REDUCES THE CORONARY THROMBOSIS OF THE RUPTURE OF PLAQUE INHIBITION PHARMACEUTICAL METHODS AND METHODS FOR TREATING THESE CONDITIONS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64502896A | 1996-05-15 | 1996-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN97084A1 true TNSN97084A1 (en) | 2005-03-15 |
Family
ID=24587368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN97084A TNSN97084A1 (en) | 1996-05-15 | 1997-05-09 | BIARYL ACETYLENES AS INHIBITORS OF METALLOPROTEINASE MATRICES |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0912496A1 (en) |
| JP (1) | JP3090957B2 (en) |
| CN (1) | CN1139570C (en) |
| AR (1) | AR007097A1 (en) |
| AU (1) | AU710759B2 (en) |
| BR (1) | BR9709077A (en) |
| CA (1) | CA2253796C (en) |
| CO (1) | CO5080759A1 (en) |
| HN (1) | HN1997000088A (en) |
| HR (1) | HRP970245B1 (en) |
| ID (1) | ID16910A (en) |
| PA (1) | PA8429301A1 (en) |
| SV (1) | SV1997000035A (en) |
| TN (1) | TNSN97084A1 (en) |
| TW (1) | TW381079B (en) |
| WO (1) | WO1997043245A1 (en) |
| YU (1) | YU18697A (en) |
| ZA (1) | ZA974031B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
| AR035478A1 (en) * | 1999-01-27 | 2004-06-02 | Wyeth Corp | AMIDA-HYDROXAMIC ACID, ACETYLLENE, BETA-SULPHONAMIDE AND PHOSPHINIC ACID AS INHIBITORS OF TACE, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
| US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
| EP1031349A1 (en) * | 1999-02-25 | 2000-08-30 | Bayer Aktiengesellschaft | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
| US7141607B1 (en) | 2000-03-10 | 2006-11-28 | Insite Vision Incorporated | Methods and compositions for treating and inhibiting retinal neovascularization |
| EP2597084B1 (en) * | 2010-07-08 | 2016-06-29 | Kaken Pharmaceutical Co., Ltd. | N-hydroxyformamide derivative and pharmaceutical containing same |
| EP3126358A1 (en) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases |
| WO2015150363A1 (en) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids and use thereof |
| CA2944617A1 (en) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3784701A (en) * | 1970-09-21 | 1974-01-08 | American Cyanamid Co | Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain |
| DE2112716A1 (en) * | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Biphenylyl-butyric acid derivs. - anti phlogistics |
| FR2378741A1 (en) | 1977-02-01 | 1978-08-25 | Fabre Sa Pierre | GARYL GOXO ISOVALERIC ACIDS WITH ANTIPHLOGISTIC AND ANTALGIC PROPERTIES |
| US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| ZA974033B (en) | 1996-05-15 | 1998-02-19 | Bayer Ag | Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors. |
-
1997
- 1997-05-09 TN TNTNSN97084A patent/TNSN97084A1/en unknown
- 1997-05-09 ZA ZA9704031A patent/ZA974031B/en unknown
- 1997-05-09 HR HR970245A patent/HRP970245B1/en not_active IP Right Cessation
- 1997-05-09 CO CO97025172A patent/CO5080759A1/en unknown
- 1997-05-12 JP JP09540980A patent/JP3090957B2/en not_active Expired - Fee Related
- 1997-05-12 PA PA19978429301A patent/PA8429301A1/en unknown
- 1997-05-12 AR ARP970101977A patent/AR007097A1/en unknown
- 1997-05-12 CA CA002253796A patent/CA2253796C/en not_active Expired - Fee Related
- 1997-05-12 HN HN1997000088A patent/HN1997000088A/en unknown
- 1997-05-12 TW TW086106283A patent/TW381079B/en not_active IP Right Cessation
- 1997-05-12 CN CNB971964564A patent/CN1139570C/en not_active Expired - Fee Related
- 1997-05-12 EP EP97923622A patent/EP0912496A1/en not_active Withdrawn
- 1997-05-12 AU AU29386/97A patent/AU710759B2/en not_active Ceased
- 1997-05-12 YU YU18697A patent/YU18697A/en unknown
- 1997-05-12 SV SV1997000035A patent/SV1997000035A/en unknown
- 1997-05-12 BR BR9709077A patent/BR9709077A/en not_active Application Discontinuation
- 1997-05-12 WO PCT/US1997/007921 patent/WO1997043245A1/en not_active Ceased
- 1997-05-14 ID IDP971606A patent/ID16910A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP970245A2 (en) | 1998-04-30 |
| WO1997043245A1 (en) | 1997-11-20 |
| JPH11511179A (en) | 1999-09-28 |
| SV1997000035A (en) | 1999-01-14 |
| CA2253796C (en) | 2003-10-28 |
| AU710759B2 (en) | 1999-09-30 |
| BR9709077A (en) | 1999-08-03 |
| JP3090957B2 (en) | 2000-09-25 |
| AR007097A1 (en) | 1999-10-13 |
| AU2938697A (en) | 1997-12-05 |
| CN1225623A (en) | 1999-08-11 |
| HN1997000088A (en) | 1997-06-18 |
| HRP970245B1 (en) | 2002-06-30 |
| TW381079B (en) | 2000-02-01 |
| ID16910A (en) | 1997-11-20 |
| CN1139570C (en) | 2004-02-25 |
| CO5080759A1 (en) | 2001-09-25 |
| YU18697A (en) | 1999-11-22 |
| CA2253796A1 (en) | 1997-11-20 |
| PA8429301A1 (en) | 2000-05-24 |
| ZA974031B (en) | 1998-02-19 |
| EP0912496A1 (en) | 1999-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN97083A1 (en) | INHIBITION OF METALLOPROTEASE MATRICES BY SUBSTITUTION OF OXOBUTYRIC BIARYL ACID | |
| TNSN97084A1 (en) | BIARYL ACETYLENES AS INHIBITORS OF METALLOPROTEINASE MATRICES | |
| MA26697A1 (en) | NOVEL GSK-3 INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| EA200101085A1 (en) | HYDROXAMIC ACIDS, DERIVATIVES OF AROMATIC SULPHONES, - METALLOPROTEASIS INHIBITORS | |
| BG102510A (en) | Inhibitors of metalloproteinase, pharmaceutical compositions containing them, their pharmaceutical application and methods and intermediate compounds for their preparation | |
| BE900481A (en) | COMPOSITION AND METHOD FOR PREVENTING OR INHIBITING RESORPTION OF ALVELOLAR BONES. | |
| ES2101358T3 (en) | INHIBITION OF TNF PRODUCTION. | |
| MA26720A1 (en) | NOVEL MONOAMINE REABSORPTION INHIBITORS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| TNSN98127A1 (en) | AZETIDINYLPROPYLPIPERIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| BR0008491A (en) | Aromatic sulfone hydroxamic acid metalloprotease inhibitors | |
| NO991674L (en) | Interleukin-1 <beta> converting enzyme inhibitor sulfonamides | |
| ATE203409T1 (en) | PHOSPHONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | |
| CA2254750A1 (en) | Inhibition of matrix metalloproteases by 2-(.omega.-aroylalkyl)-4-biaryl-oxobutyric acids | |
| JPH11504646A (en) | Peptide compounds inhibiting the release of metalloproteases and TNF and their therapeutic use | |
| DE69811360D1 (en) | DIAZEPINOINDOLONE AS A PHOPHODIESTERASE 4 INHIBITORS | |
| TNSN97082A1 (en) | INHIBITION OF METALLOPROTEASE MATRICES BY SUBSTITUTION OF PHENETYLE COMPOUNDS | |
| CA2266759A1 (en) | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | |
| DE69735230D1 (en) | SULPHONAMIDE-SUBSTITUTED ASPARAGINIC ACIDS AS INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYMES | |
| TNSN97085A1 (en) | OXYBUTERIC SUBSTITUTION OF ACIDS AS METALLOPROTEASE MATRIX INHIBITORS | |
| US5627173A (en) | Phosphonoacetic acid derivatives and their use for treating degenerative joint disorders | |
| TH12333B (en) | Inhibition of matrix methalloprotein by substitutedphenethyl compounds. | |
| TH35864A (en) | Inhibition of matrix methalloprotein by substitutedphenethyl compounds. | |
| ECSP972114A (en) | BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE | |
| ECSP972112A (en) | INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED FENETILE COMPOUNDS | |
| ECSP972113A (en) | INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED BIARILOXOBUTIRIC ACIDS |